336 related articles for article (PubMed ID: 19118059)
1. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
Cortes J; Di Cosimo S; Climent MA; Cortés-Funes H; Lluch A; Gascón P; Mayordomo JI; Gil M; Benavides M; Cirera L; Ojeda B; Rodríguez CA; Trigo JM; Vazquez J; Regueiro P; Dorado JF; Baselga J;
Clin Cancer Res; 2009 Jan; 15(1):307-14. PubMed ID: 19118059
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
5. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
[TBL] [Abstract][Full Text] [Related]
6. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.
Leyland-Jones B; Gelmon K; Ayoub JP; Arnold A; Verma S; Dias R; Ghahramani P
J Clin Oncol; 2003 Nov; 21(21):3965-71. PubMed ID: 14507946
[TBL] [Abstract][Full Text] [Related]
9. A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.
Venturini M; Bighin C; Puglisi F; Olmeo N; Aitini E; Colucci G; Garrone O; Paccagnella A; Marini G; Crinò L; Mansutti M; Baconnet B; Barbato A; Del Mastro L
Breast; 2010 Oct; 19(5):333-8. PubMed ID: 20185313
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer.
Theodoulou M; Batist G; Campos S; Winer E; Welles L; Hudis C
Clin Breast Cancer; 2009 May; 9(2):101-7. PubMed ID: 19433391
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.
Amadori D; Milandri C; Comella G; Saracchini S; Salvagni S; Barone C; Bordonaro R; Gebbia V; Barbato A; Serra P; Gattuso D; Nanni O; Baconnet B; Gasparini G
Eur J Cancer; 2011 Sep; 47(14):2091-8. PubMed ID: 21665463
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
Robert N; Leyland-Jones B; Asmar L; Belt R; Ilegbodu D; Loesch D; Raju R; Valentine E; Sayre R; Cobleigh M; Albain K; McCullough C; Fuchs L; Slamon D
J Clin Oncol; 2006 Jun; 24(18):2786-92. PubMed ID: 16782917
[TBL] [Abstract][Full Text] [Related]
13. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.
Bianchi G; Albanell J; Eiermann W; Vitali G; Borquez D; Viganò L; Molina R; Raab G; Locatelli A; Vanhauwere B; Gianni L; Baselga J
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5944-51. PubMed ID: 14676119
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
Nisticò C; Bria E; Vaccaro V; Cuppone F; Fornier M; Sperduti I; Carpino A; Izzo F; Tropea F; Cognetti F; Terzoli E
Anticancer Drugs; 2009 Feb; 20(2):109-14. PubMed ID: 19209027
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
Seidman AD; Berry D; Cirrincione C; Harris L; Muss H; Marcom PK; Gipson G; Burstein H; Lake D; Shapiro CL; Ungaro P; Norton L; Winer E; Hudis C
J Clin Oncol; 2008 Apr; 26(10):1642-9. PubMed ID: 18375893
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.
Andre F; Campone M; O'Regan R; Manlius C; Massacesi C; Sahmoud T; Mukhopadhyay P; Soria JC; Naughton M; Hurvitz SA
J Clin Oncol; 2010 Dec; 28(34):5110-5. PubMed ID: 20975068
[TBL] [Abstract][Full Text] [Related]
17. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
Ruiz M; Salvador J; Bayo J; Lomas M; Moreno A; Valero M; Bernabé R; Vicente D; Jiménez J; Lopez-Ladrón A
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1085-90. PubMed ID: 18365200
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
[TBL] [Abstract][Full Text] [Related]
20. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
